Select Page

Press Releases

Sign up to get full access to all our latest Press Releases

Closing of Second Tranche of Private Placement Financing, Amendment to Terms of Secured Debt and Director Change

September 22, 2023


Corporate Update BURLINGTON, Ontario – September 22, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed on $310,000 in a second tranche of its previously announced private placement financing (the “Financing”) bringing the total...

Rapid Dose Provides Update on Private Placement

September 14, 2023


BURLINGTON, Ontario – September 14 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated July 24, 2023 announcing a first tranche closing of approximately $1,500,000, the Company has received an extension from the...

Rapid Dose Announces Results of Annual General and Special Meeting of Shareholders

August 4, 2023


BURLINGTON, Ontario – August 2, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce the voting results from its annual general and special meeting of shareholders (the “Meeting“) held on August 1, 2023. All matters presented to the...

MARK UPSDELL FILES EARLY WARNING REPORT

July 26, 2023


Burlington, Ontario, July 24, 2023 – Mark Upsdell, a director and officer of Rapid Dose Therapeutics Corp. (the “Company”), announces that he has acquired ownership of additional securities of the Company by way of a non-brokered private placement pursuant to a settlement of debt.  As...

Rapid Dose Closes First Tranche of Private Placement Financing

July 24, 2023


BURLINGTON, Ontario – July 24, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed on $1,469,445 in a first tranche of its previously announced private placement financing (the “Financing”) for up to $5,000,000 of...

Rapid Dose Therapeutics Corp. Corporate Update

July 7, 2023


July 7, 2023 – Burlington, ON: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to share an update on its current progress in various segments of its business. The Annual General and Special Meeting of the shareholders of Rapid Dose Therapeutics...

Rapid Dose Therapeutics Reports Fiscal Year 2023 Financial Results

June 29, 2023


Burlington, Ontario – June 28, 2023– Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), today reported its financial results for the year ended February 28, 2023. The Company is pleased to be able to report on its results for the fiscal year 2023...

Rapid Dose Announces Proposed Private Placement Financing

June 5, 2023


BURLINGTON, Ontario – June 2, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete a private placement financing (the “Financing”) for up to $3,000,000 of gross proceeds, consisting of up to 3,000,000 units (the “Units”)...

Rapid Dose Announces Change of Auditor

May 18, 2023


BURLINGTON, Ontario – May 17, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces that it has changed its auditor from MNP LLP (“Former Auditor”) to SRCO Professional Corporation, Chartered Professional Accountants (“Successor Auditor”). At the request of the Company, the...

Rapid Dose Therapeutics Launches QuickStrip™ Dental Products in the Canadian Market QuickStrip™ Xylitol and Lidocaine to offer consumers needle-free options for dental procedures

May 10, 2023


BURLINGTON, Ontario – May 10, 2023- Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: ·...

1 2 3 4 5 6 7 8 9 10 11 12 14